United Therapeutics Corp UTHR

United Therapeutics Corporation es una empresa de biotecnología. La empresa se enfoca en el desarrollo y comercialización de productos para el tratamiento de condiciones crónicas y potencialmente mortales. La empresa comercializa y vende cuatro terapias comerciales en los Estados Unidos para tratar la hipertensión arterial pulmonar (HAP): Remodulin (treprostinil) Inyección; Tyvaso (treprostinil) Solución para Inhalación (Tyvaso); Orenitram (treprostinil) Tabletas de Liberación Prolongada (Orenitram); y Adcirca (tadalafil) Tabletas (Adcirca). La empresa también comercializa y vende un producto de oncología en los Estados Unidos, Unituxin (dinutuximab) Inyección (Unituxin), que está aprobado para el tratamiento del neuroblastoma. La empresa también está involucrada en la investigación y desarrollo en etapas iniciales de una serie de tecnologías relacionadas con el trasplante de órganos.

• Zacks Investment Research 1 oct

  Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback

  A U.S. District Court ruled that two claims of United Therapeutics' '327 patent are valid and infringed by Liquidia's lead drug Yutrepia, causing a 57% decline in LQDA stock. Liquidia plans to remove the PH-ILD indication from Yutrepia's label to potentially preserve the drug's availability, narrowing its addressable market. The ruling creates significant uncertainty around Yutrepia's commercial outlook, with United Therapeutics seeking injunctive relief while Liquidia pursues appeals.

  

• Zacks Investment Research 1 oct

  UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%

  United Therapeutics won a patent infringement ruling against Liquidia Technologies, with the court finding that Liquidia's Yutrepia infringes two claims of UTHR's patent covering inhaled treprostinil for PH-ILD treatment. Yutrepia may lose its PH-ILD label or face market removal, reducing competition for UTHR's Tyvaso products and potentially resulting in monetary damages for past infringement.

  

• Zacks Investment Research 1 oct

  United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last?

  United Therapeutics shares surged 12.5% following a Delaware court ruling that Liquidia's Yutrepia infringes on UTHR's patent for inhaled treprostinil, potentially restricting competition for UTHR's Tyvaso products. However, the stock faces headwinds as consensus EPS estimates were revised 1.4% lower over the past 30 days, and the company is expected to report declining earnings and flat revenue growth.

  

• Zacks Investment Research 11 sept

  LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?

  Liquidia's lead drug Yutrepia has gained significant market traction with over 5,000 patients started on therapy as of July 2026, but the stock has underperformed due to heavy reliance on a single product, ongoing patent litigation with United Therapeutics, competitive pressures, and rising R&D costs. Analysts recommend avoiding the stock due to an unfavorable risk-reward profile.

  

• Zacks Investment Research 3 sept

  FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis

  United Therapeutics announced FDA acceptance of a supplemental new drug application for nebulized Tyvaso to treat idiopathic pulmonary fibrosis (IPF), with a regulatory decision expected in late April 2027. The TETON phase III studies demonstrated statistically significant improvements in lung function, including a 111.8 mL FVC benefit, reduced clinical worsening, and favorable secondary endpoints. If approved, Tyvaso would be the first FDA-approved inhaled anti-fibrotic treatment for IPF.